Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01491737
Show Display Options
Rank Status Study
1 Recruiting A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Aromatase Inhibitor;   Drug: Induction Chemotherapy;   Drug: pertuzumab;   Drug: trastuzumab

Indicates status has not been verified in more than two years